After an exceptionally successful inaugural launch last year, the 2^nd Annual Glioblastoma Drug Development Summit returns this year in an exclusive virtual format.

GBM Drug Development is the only devoted meeting for large pharma, biotech and pioneering academics which guarantees to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat glioblastoma, an extremely aggressive cancer with a huge medical unmet need.

Confronting specific and applied drug development obstacles with inadequate successful treatments, such as the knowledge of glioblastoma’s mechanisms of resistance and lack of penetration via the blood brain barrier, the 2^nd GBM Drug Development Summit will help neuro-oncologists, neurosurgeons  and oncology professionals from biopharma effectively translate their drug candidates into human clinical trials, whilst optimizing the clinical development process itself to evade further clinical failures.

Brought direct to your home office with a jam-packed agenda and online virtual networking opportunities, this exclusive virtual summit will delve into the common challenges with developing GBM therapies, whilst striving to advance safe and effective therapeutic breakthroughs to patients in need.

Join us as we unite drug developers and academics on a dedicated virtual platform to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients.

Download the draft agenda to see key topics that will be covered.